Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue – a review by unknown
Fedchenko and Reifenrath Diagnostic Pathology 2014, 9:221
http://www.diagnosticpathology.org/content/9/1/221REVIEW Open AccessDifferent approaches for interpretation and
reporting of immunohistochemistry analysis
results in the bone tissue – a review
Nickolay Fedchenko1,2* and Janin Reifenrath1Abstract
Background: Immunohistochemistry (IHC) is a well-established, widely accepted method in both clinical and
experimental parts of medical science. It allows receiving valuable information about any process in any tissue, and
especially in bone. Each year the amount of data, received by IHC, grows in geometric progression. But the lack of
standardization, especially on the post-analytical stage (interpreting and reporting of results), makes the comparison
of the results of different studies impossible.
Methods: Comprehensive PubMED literature search with a combination of search words “immunohistochemistry”
and “scoring system” was performed and 773 articles describing IHC results were identified. After further manual
analysis 120 articles were selected for detailed evaluation of used approaches.
Results: Six major approaches to the interpretation and presentation of IHC analysis results were identified,
analyzed and described.
Conclusions: The overview of the existing approaches in evaluation and interpretation of IHC data, which are
provided in the article, can be used in bone tissue research and for either better understanding of existing scoring
systems or developing a new one. Standard multiparametric, semiquantitative IHC scoring systems should simplify
and clarify the process of interpretation and reporting of received data.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_221
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The main aim of any histopathological investigation is the
identification of a pathological process, therefore special
diagnostic features are necessary. Revealing of such fea-
tures in bone tissue is concerned with several differences
compared to other tissues. They start from the very begin-
ning of the long chain of bone specimens obtaining and
preparation: bone tissue needs prolonged fixation, often
decalcification, special media infiltration and embedding,
special equipment for cutting of the tissue specimens
(heavy-duty microtomes, diamond circular or wire saws),* Correspondence: fedchenko.nick@gmail.com
1Small Animal Clinic, University of Veterinary Medicine, Foundation,
Bünteweg 9, 30559 Hannover, Germany
2Department of Pathological Anatomy and Forensic Medicine, SE
“Dnipropetrovsk Medical Academy of Health Ministry of Ukraine”,
Dzerginskogo st. 9, 49044 Dnipropetrovsk, Ukraine
© 2014 Fedchenko and Reifenrath; licensee Bi
the Creative Commons Attribution License (ht
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.and even grinding machines for section thinning and
grinding [1,2].
Unfortunately there is still no staining procedure
invented, which is able to obtain specific information
about all desired structures, such as osteoid, mineralized
bone matrix, glycosaminoglycans and many others on one
slide. To receive important information scientists choose
the relevant staining method from a wide range of avail-
able ones nowadays. Many excellent reviews presented a
variety of staining methods, and their pros and cons
[1,3-6]. Among of all methods, immunohistochemistry is a
well-established tool, which is widely used to help identify-
ing a wide spectrum of specific pathological processes and
which is used in experimental research involving bone tis-
sue. Besides descriptive analyses, multiparametric, semi-
quantitative scoring systems for evaluating different boneoMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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topathologic information in biomedical research [7-9].
In general, one of the most important attribute of any
scientific research is its language or nomenclature. The
first widely accepted standardization of bone tissue no-
menclature was made by Michael Parfitt in 1987 [10]. It
was widely accepted and improved markedly the ability of
bone researchers to communicate with each other and
with nonspecialists, leading to a broader understanding
and appreciation of bone research data. After 25 years
these recommendations were revised and published in
2012 by David W Dempster and his coauthors [11].
Contrary to the general bone tissue nomenclature,
there is still a huge gap in the standardization of IHC
methods. IHC is a multistep procedure, and each step is
vital. The importance of using standardized rules and
environment on each stage of the method is stated in
various articles and monographs [12-25]. According to
existing conceptions, all variables implying on IHC
methods are divided into 3 groups:
1) Pre-analytical variables of IHC tests include Any and
all steps in tissue processing, starting from tissue
sample obtaining (prolonged ischemia, delayed
fixation, etc.), type and length of fixation,
decalcification, and elements of tissue handling
(proper specimens orientation, careful notation of
surgical margins, slicing into sections at 2 to 5 mm
intervals, adequate naming, etc.). Unfortunately,
pre-analytical variables cannot be controlled closely,
unless you perform all the stages by your own or in
certified laboratory [12,15,17,18,21-23].
2) Analytical variables of IHC tests include slide
thickness, choosing of antibody clones and their
titration, choosing the detection systems and, of
course, antigen retrieval (AR) procedure. Current IHC
detection systems include peroxisae-anti-peroxidase,
the avidin-biotin complex, the biotin-streptavidin
amplified systems, tyramine amplification method,
immuno–rolling circle amplification, and the polymer
enzyme system [26,27]. Antigen retrieval procedures
include enzymatic digestion, acid treatment, alkaline
hydrolysis, detergent treatment, using the urea
solution, refixation with Zn-solution, freeze and
thawing, freeze and drying, and of course heating
[14,27-29]. AR method should be carefully selected,
because many antigens are very sensitive for selected
approach, and AR may either enhance the result or
completely destroy the target substance of interest [30].
3) Post-analytical variables of IHC tests include
interpretation and reporting of the results [31]. Despite
all existing recommendations, post-analytical variables
are the most frivolous part of many experiments using
IHC diagnostics. Misinterpretation of positive andnegative results, inappropriate morphological context,
unclear scoring systems, and inadequate statistical
analysis make it impossible to perceive any data and
compare it to other scientific information.
The last step of IHC variables and particularly the scor-
ing systems are the main topic of this review. The funda-
mental characteristics of a scoring system were suggested
by Crissman et al., and included the following: (1) scoring
system should be definable, (2) it should be reproducible,
and (3) it should produce meaningful results [32]. Gibson-
Corley et al. also described some key principles for an ap-
propriate scoring system and data evaluation [33]:
– “Masking” of the experimental material to reduce
the subjectivity of valued scores;
– a thorough “Examination” of all tissues/slides with
creation of a context for scoring tissue lesions;
– specifying “Lesion parameters”, which then could be
used as score categories;
– using a clear “Scoring definitions” will improve
understanding of presented data and increase
repeatability of scoring system;
– whenever possible, use “Interpretation Consistency”
which imply that all the samples are scored by the
same scientist in a reasonable period of time.
Semiquantitative scoring systems are widely used to
convert subjective perception of IHC-marker expression
by histopathologists into quantitative data, which is then
used for statistical analyses and establishing of the conclu-
sions. Without scoring system the description of received
data can be provided only with subjective perception,
expressed in such adjectives as “strong”, “weak”, “absent”
with modifiers as “more” or “less”, like Sojo et al. in evalu-
ation of VEGF and BMP-2, −4 on lengthened rat femurs
[34]. Of course, this approach is used by each pathologist
while examining the slides, but without conversion into a
scoring system – they are just subjective expressions of as-
sessments of solely one pathologist. To reduce subjectivity
it is recommended to have at least more than one obser-
ver in the study [35].
Most semiquantitative scoring systems usually include
multiple parameters which are separately quantified on an
ordinal scale and finally combined in a total score. Average
scores of the different experimental groups can then be
compared by non-parametric statistical tests [7]. The se-
lection of the parameters should be based on the scientific
hypothesis or question together with the morphological fea-
tures of expression of IHC markers which are used in an
experiment. The “golden standard” in IHC scoring is de-
fined for the evaluation of only 3 markers so far: Her2/neu,
estrogen (ER), and progesterone (PR) for which testing
guidelines have been developed [36].
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scoring system, which might be the best possible way to
answers the particular scientific question. Lack of stand-
ard scoring systems for most IHC markers and particu-
larly for bone tissue leads to the impossibility of the
comparison of the results with other studies [37,38].
The present review is aimed to provide the reader with
an overview of the existing approaches in evaluation of
IHC markers which can be used in bone tissue research
and for either better understanding of existing scoring
systems or developing a new one.Review
Methods
Inclusion criteria for comprehensive literature search were
a description of IHC results with or without scoring system.
The priority was given for the scoring systems for IHC
markers that can be used in bone tissue studies. Among
such markers were Vascular Endothelial Growth Factor
(VEGF), Bone Morphogenic Proteins (BMP), Osteocalcin
(OCN), Osteopontin (OPN), and some others with devel-
oped scoring systems. Exemplary for VEGF and BMP the
tendency in ongoing immunohistochemistry researches is
shown in Figure 1 – their number is growing in geometric
progression. During last 20 years (from January 1994 to July
2014) the number of articles mentioning VEGF was more
than 50000. Bone Morphogenic Protein was mentioned in
9530 articles (Figure 2).
Using a comprehensive PubMED search with a com-
bination of search words “immunohistochemistry” and
“scoring system” 773 articles were identified. After fur-
ther manual analysis 120 articles were selected for de-
tailed evaluation of used approaches for interpretation



























Figure 1 Count of articles, mentioning “VEGF” from 1994 to 2014 accResults
A widely accepted scoring system for immunohistochem-
istry does not exist yet. The amount of IHC markers used
in clinical and experimental research is constantly grow-
ing, and so do the amount of researches and data in the
field. A closer manual analysis of the selected 120 articles
allowed us to identify six major approaches to the inter-
pretation and presentation of received results (Figure 3).
Description of morphological parameters
This approach is the example of pure qualitative analysis of
received information. Verbal description works well if the
amount of slides is small and no further statistical analysis
of received information is planned; for example, for pilot
studies or if IHC analysis is not the main method in an ex-
periment. For presenting the data in the article authors use
a literal description of a histological picture (which cells or
tissue components were immunopositive) and properties of
IHC expression (weak/moderate/strong intensity, staining
pattern, background, etc.) [34,39-49]. Detailed examination
and description of alkaline phosphatase (ALP), collagen
type I (COL I), osteonectin (OTN), OPN, OCN, and bone
sialoprotein (BSP) expression in cellular and matrix compo-
nents of bone was performed by Knabe et al. [49].
Unfortunately, if the results are presented only in a de-
scriptive form, they cannot be compared to other studies
directly. However, sometimes such method gives very
valuable details, which may be hidden by scoring system
categorization [33,50].
Evaluation of number of IHC-positively stained cells and
structures
This is quite simple and commonly used approach in
evaluating IHC results. Authors count the absolute quan-










































































Figure 2 Count of articles, mentioning “Bone Morphogenic Protein” from 1994 to 2014 according to PubMed.
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ample, Ishihara et al. counted the number of BMP-2
stained cells in decalcified rabbit nasal bone [52].
IHC markers (factor VIII, CD31, CD34, CD105, VEGF
and its receptors, etc.) are often used to establish micro-
vessel density (MVD) [54-64]. This parameter is often pre-
sented as a number of microvessels per square millimeter
or mean value with standard deviations. For including a
microvessel into a count it should be presented as any
brown-stained endothelial cell or endothelial-cell cluster
that was clearly separate from adjacent microvessels,
tumor cells, and other connective-tissue elements [65].
The main problem of cell and structures counting, that
it must be very clearly mentioned which cells and/or
structures were considered to be “positive”. If the IHC
staining is not homogeneous, cell populations withFigure 3 Ratio of different IHC data interpretation and presentation mdifferent staining properties can be counted separately
[66]. Sometimes background staining may lead to misin-
terpretation [25] and as for the bone tissue, the expres-
sion of many IHC markers is observed not only in the
cells, but in the osteoid and bone matrix either [67,68].
Results in studies using this method in most cases are
presented as mean values of positively stained cells (and/
or structures) among counted experimental groups with
their standard deviations [51-64]. If the IHC marker has a
high affinity to cells, then the process of positive cells
counting may be optimized by some special methods [69].
Evaluation of IHC-positively stained cells and/or area ratio
This approach seems to be more time consuming, there-
fore it is more informative. Researchers count the per-











ethods in selected articles.
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tomated with the use of special plugins for computer
counting of general amount of cells and positively
stained cells [71].
Because slides are stained separately for each IHC
marker (if otherwise is not stated), the % of positively
stained cells is counted separately either. The relation of
positively stained cells sometimes is presented in the la-
beling index (the ratio number of positively stained
cells/total number of cells × 100) [72,73]. Wittenburg
et al. evaluated for OCN, OTN, OPN, COL I, CD34, and
CD68 the positively stained areas in relation to the total
bone surface per section in percentage [2].
As in the second approach, where absolute quantity of
cells was calculated, in scoring of % of immunopositive
cells all criteria should be clearly mentioned: which cells
and areas were considered to be “positive” or “negative”
and why.
The measurement of both, percentage of positively
stained cells and area, was performed by Ramazanoglu
et al. in the investigation of COL I, BMP-2\4, OCN, and
OPN [67]. In this study immunopositive cells were counted
in each region of interest (ROI) using a counting grid and
their proportion among the total counterstained cell popu-
lation was analyzed. For COL I stained areas of the ROI
were digitally marked and the percentage of stained areas
was determined using a computer program.
Usually the combination of quantitative and qualitative
parameters leads to expression of received data in a
combined scoring systems, which are described later in
this article. But the amount of positively stained cells
and their relations can be expressed via a simple qualita-
tive scoring system, when certain percentage is given a
certain score value [74,75]. Such approach was per-
formed by Sulzbacher et al.: “++” score was given for
50–95% of positive stained tumor cells; “+” score for
10–49% of tumor cells positive; “−“ score when less,
than 10% of tumor cells or no visible staining was ob-
served [76]. Semiquantitative scoring with numbers in-
stead of “+” signs can be used either, like did DeRycke
et al. in their evaluation of S100A1 expression in ovarian
and endometrial endometrioid carcinomas [77]. In this
case investigated slides were assigned a score of 0 (no
staining), 1 (<10% of neoplastic cells staining), 2 (10%–
50% of neoplastic cells staining), or 3 (>50% of neoplas-
tic cells staining) [77,78].
Results in studies, measuring the relations of IHC-
stained cells and areas, are presented as mean values for
% of positively stained cells with their standard devia-
tions [2,72-75,79,80].
Qualitative scoring
As already described in the first part of this article,
qualitative interpretation of IHC data is commonly usedamong scientists. In addition to the description of the
evaluated parameters scientists may use qualitative scor-
ing systems to interpret received data, usually the force
of IHC staining in different investigated areas. Score
ranks usually lie in a range from “negative” (mostly
marked as “-”) to “positive”, which may be signed with
different amount of “+” depending on how many other
categories lay between these border parameters [79,81-84].
Most common spectrum of categories, describing different
force of IHC expression in investigated groups, include:
“negative”(−), “weak”(+), “moderate”(++), “strong”(+++)
and their variations [85-91]. If the categories are signed
with a numeric value instead of signs, then this approach
transforms from qualitative to semi-quantitative [16,20].
Osteoprotegerin (OPG), receptor activator of nuclear
factor-k ligand (RANKL), ALP, OPN, VEGF, tartrate-
resistant acid phosphatase (TRAP), COL I, and OCN were
assessed using a semi-quantitative ranking that ranged
from 0 for no labeling to 4 for intense labeling in the of
onlay bone graft remodeling by Hawthrone et al. [92].
Same approach with some extension of scoring groups
was used in evaluation of VEGF, BMP-2 and core-binding
factor alpha 1 (CBFA1) by Guskuma et al. [93].
Another variant of data presentation is scoring the
force of IHC expression among different cell populations
and tissue components. An example of this method is
demonstrated by Yu et al. for scoring immunoreactivity
for BMPs, BMP antagonists, receptors, and effectors in
different cell populations during nonstabilized fracture
healing [94]. Similar method was used by Li et al. for
reporting relative abundances of BMP-2 and other IHC
markers in uterine structural components and cells
[90,95] and by Koerdt et al. in the study of the role of
oxidative and nitrosative stress in autogenous bone
grafts to the mandible [96].
A more complicated method of assigning different cri-
teria for staining intensity was used by Ding et al., which
included assignment of the intensity of staining using a
scale of 0–10 (with 0 indicating a lack of brown immu-
noreactivity and 10 reflecting intense dark brown stain-
ing) by three observers. All observers evaluated all slides
and observations outside of the 5th to 95th percentile of
the remaining observations were considered outlying
data and were excluded from analysis. After that the
mean was calculated and the results were converted into
grades: 1–3 score was assigned “+”, 4–6 was “++”, more
than 7 was “+++” [97].
If the results in reports are presented as graded on a
scale from “ − ” to “ +… + ” they may look more demon-
strative, but the range of statistical methods is limited
without a conversion to a numeric ordinal score for cor-
responding staining intensity [98]. However, only two
groups, showing “positive” and “negative” expression of
IHC marker, may be already compared statistically [99].
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The most universal way to create a scoring system is to
combine all existing approaches into a new one. There
are quite a lot of examples of combined multiparameter
scoring systems and in this review we will focus on the
most recent and widely used ones. In multiparameter
scoring systems the semiquantitative approach is used:
investigated parameters are valued points from 0 to 4, 6
or even 18 depending only on depth of categorization of
the used scoring systems. A small number of score cat-
egories may reduce the sensitivity of the scoring system,
but a large number of ordinal scores may cause difficulty
in score assignment as the distinctions between categor-
ies become less obvious. This leads to a less repeatability
of the scoring system with large number of categories.
Some authors suggest that to maximize detection and
repeatability of the scoring system, it should contain an
average of four to five score levels [100,101].
Simple combinative scoring system for evaluation of
OCN and OPN expression was used by Bondarenko
et al. [68]. Combination of quantitative and qualitative
criteria in the semiquantitative scoring system was used
in the study of VEGF-A, VEGF-C and fibroblast growth
factor 2 (FGF-2) by Torre et al. [102]. The authors com-
bined cells percentage with a force of IHC-staining and
assigned to each field a value from 0 to 4 (0, negative; 1,
<5% of the cells with positive staining; 2, between 5 and
50% of the cells with positive staining; 3, more than 50%
of the cells with weak staining and 4, more than 50% of
the cells with strong staining). The characteristics of se-
lected scoring systems are shown in the Table 1. Similar
approach was demonstrated by Jin et al. for evaluation
of BMP-2/4, −5 and BMP protein receptor, type IA, but
they did not count the intensity of staining [103].
There are a lot of different approaches in establishing
the evaluation criteria and corresponding scoring points.
They are closely connected to the scientific goal of the
experiment and properties of used IHC markers. Most
criteria include percentage of positively stained cells and
intensity of observed staining [104]. Unfortunately it is
not always clear, how authors manipulate with their
scoring systems. For example, Megumi et al. scored the
percentage of BMP-7-positive stained cells and the in-
tensity of the staining, but it is not clear how theTable 1 Examples of combinative scoring system for histomo
Score Bondarenko et al. for OCN* [68] Bondarenko et al. fo
0 - -
1 <25% Expression in cells onl
2 25-50% Expression in cells and
3 50-75% Focal expression in m
4 >75% Diffuse expression in m
*OCN expression was evaluated as a percentage rate of immunopositive peri-implaintensity (valued from 1+ to 3+) implied the percentage
(also presented in score values ranging from 1+ to 3+)
[105]. The scoring system is very important in further
statistical analysis of received information, because it
directly determines the variability of achieved results
[100,106] and statistical validity directly depends on the
variability of representation [107]. Sometimes authors
can perform simple manipulations to extend the range
of score values. For example, Klein et al. for VEGF scor-
ing added proportion score values to staining intensity
score and received a range of values points from 0 to 6
[108]. Two years later the same author increased the
range of points from 6 to 9 by changing arithmetical op-
eration from addition to multiplication (Table 2) [109].
Such manipulation increase the variation row, which
gives more statistically reliable results [110].
Three examples of widespread combined scoring sys-
tems are Allred-score [96], immunoreactive score (IRS)
[111] and H-score [112], which are commonly used for
IHC evaluation of progesterone and estrogen receptors.
Although these receptors are not expressed in bone tis-
sue, these scoring systems considered to be “gold stand-
ard” in IHC-data evaluation and presentation They are
widely accepted and recommended by leading associa-
tions and organizations [22,36,113,114]. The Allred scor-
ing system combines the percentage of positive cells and
the intensity of the reaction product in most of the ex-
amined fields. The two scores are added together for a
final score with eight possible values. Scores of 0 and 2
are considered negative. Scores of 3 to 8 are considered
positive (Table 3) [115,116].
A similar approach to Allred score is demonstrated in
so-called “quickscore” system, with the differences in
assigned values from 1 to 6 in proportion category A (1 =
0-4%, 2 = 5-19%, 3 = 20-39%, 4 = 40-59%, 5 = 60-79%, 6 =
80-100%), also multiplication is recommended instead of
addition for processing of final score range [117]. In litera-
ture Allred score is used for BMP-6 [118,119] and OPN
[120] expression evaluation. According to Kejner et al.
they used this scoring system for BMP-6 evaluation, but
after authors modifications the score range was reduced to
4 categories, which described only intensity of staining: 0
(Low), 1 (Mid-Low), 2 (High-Mid), or 3 (High), which is
actually not an Allred score anymore [119].rphometry
r OPN [68] Torre et al. for VEGF-A, VEGF-C and FGF-2 [102]
Negative
y <5% of the cells with positive staining
osteoid Between 5 and 50% of the cells with positive staining
ature bone >50% of the cells with weak staining
ature bone > 50% of the cells with strong staining
nt bone tissue to all peri-implant bone area.
Table 2 Scoring system used by Klein et al
A % of IHC +
labeled cells
B intensity of IHC
reaction
Final score
0 = 0% 0 = no reaction A + B = range from 0 to
6 [108]
1 = <30% 1 = weak
2 = 30-60% 2 =mild A × B = range from 0 to
9 [109]
3 = >60% 3 = strong






of A and B)
0 = no positive cells 0 = no color
reaction
0-1 = negative
1 = <10% of positive
cells
1 =mild reaction 2-3 =mild
2 = 10-50% positive cells 2 =moderate
reaction
4-8 =moderate
3 = 51-80% positive cells 3 = intense
reaction
9-12 = strongly positive
4 = >80% positive cells Final IRS score (A × B): 0-12
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multiplication of the percentage of cells with staining in-
tensity ordinal value (scored from 0 for “no signal” to 3
for “strong signal”) with 300 possible values. In this sys-
tem, <1% positive cells is considered to be a negative re-
sult [112,121]. According to Dabbs et al., H-score has a
broader dynamic range compared to Allred score [9].
The immunoreactive score (IRS) gives a range of 0–12
as a product of multiplication between positive cells pro-
portion score (0–4) and staining intensity score (0–3)
(Table 4) [111]. IRS was used for expression of wide
spectrum of IHC markers (BMP and its receptors, VEGF,
vWF and others) in bone studies by Koerdt et al.
[122,123]. For evaluation of BMP-6 reaction the IRS
score with some modifications was used by Raida et al.,
but in the example used by authors the calculation of
IRS is performed by summarizing of different score
values [124]. Even more controversial approach in calcu-
lation of IRS score we can observe in the evaluation of
BMP-2 score by de Carvalho et al., where authors men-
tioned, that they scored percentage of positive cells, but
there were only two categories of stain intensity: score 1
(absent or weak expression) and score 2 (strong expres-
sion); and it is unclear what further manipulations au-
thors performed with the score values – addition or
multiplication [125].
If the examined sample stains for IHC marker hetero-
geneously, then each intensity of staining is scored inde-
pendently and the results are summed. The example of
such approach is given by Kraewska et al.: when a speci-
men contained 50% of the tumor cells with moderate in-
tensity (2 × 2 = 4), 25% of tumor cells with intense
immunostaining (1 × 3 = 3), and 25% of cells with weak
intensity (1 × 1 = 1), the score was 4 + 3 + 1 = 8 [126].Table 3 Allred scoring system
Proportion score A Positive cells, % Intensity Intensity score B
0 0 None 0
1 <1 Weak 1
2 1 to 10 Intermediate 2
3 11 to 33 Strong 3
4 34 to 66 Final score range (A + B): 0-8
5 ≥67Allred score, “quickscore”, H-score, and IRS are aimed
only to the cellular staining evaluation and without
modifications cannot be used for expression of extracel-
lular staining.Evaluation of objective parameters and automated
approaches for calculation and scoring
Calculation of objective parameters such as optical density
of positively IHC stained areas is a very perspective field,
because until today the most common approach for ana-
lysis and interpretation of the IHC staining is a time-
consuming and subjective manual procedure [71]. Due to
broad scoring categories, nonstandardized approaches,
subjectivity and variability of purely visual inspection the
method of manual scoring IHC slides is less than precise
[127]. In this review we briefly discuss major aspects of
evaluating and scoring of some IHC parameters, which
can be used in bone tissue research. One of the parame-
ters that can be obtained and measured after IHC of bone
tissue is Integrated Optical Density (IOD). This parameter
was evaluated by Dehao et al. for VEGF expression [128]
and by other authors for different IHC markers [129,130].
Results in experiments, measuring objective parameters,
are presented in mean values of calculated parameter with
their standard deviations. Of course, measuring objective
parameters significantly reduces amount of subjective
judgment which may implement the results. But high con-
sumption of observer’s time makes it almost impossible to
use any manual scoring in a large screening application. In
such cases using personal computers with special analyt-
ical software may be the only alternative. The automation
has penetrated in almost all fields of IHC [131,132], but
interpretation and analysis of results remain an unreached
milestone. Some products for automated measure are
already present on the market and used in different exper-
iments [71,127,133-136]. Kraan et al. compared manual
and automated measurements of IOD and number of
immunopositive cells in their work [137].
Rizzardi et al. compared pathologists manual scoring
system with digital image analysis systems using digital
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bining area and staining intensity (OD × %Pos) [78].
Unfortunately, available automated systems are too far
from ideal: some programs are not able to isolate indi-
vidual cells, but most are still not capable for interpret-
ation of morphological features [127]. Another major
disadvantage of such systems are the costs and special
skills required for the introduction and maintenance of
all system components (software, hardware) [137]. On
the other hand, manual scoring is not suitable for a large
massive of data analysis [138], and in the authors opin-
ion, the improvement of automated image analysis sys-
tems is just a question of time.
Conclusions
Summarized, the six listed approaches for evaluation, inter-
pretation, and presentation of received experimental IHC
information contain significantly different data. Which ap-
proach is chosen depends only on the researcher’s opinion.
Selection of an existing or developing of a new scoring sys-
tem should be performed as early as possible, probably on
such stages as developing the experimental design, purposes
formationing and choosing tissue sampling parameters.
This review gives an overview on currently available ap-
proaches for evaluating and presenting data of bone im-
munohistochemistry, which may also be used in any other
IHC field. In the authors opinion, a good scoring system is
one of the key factors for any experiment. It helps to con-
nect a specific scientific question with a clear presentation
of achieved results. Properly selected or even newly devel-
oped scoring system will significantly increase the scien-
tists productivity, save time and money.
Individual scoring systems for particular IHC marker
may be the best possible way to answer the special scientific
question, but lack of standard scoring systems for most
IHC markers, and particularly for bone tissue, leads to the
impossibility of the comparison of the results with other
studies. Developing of standard multiparametric, semiquan-
titative IHC scoring systems for bone tissue studies should
simplify and clarify the process of interpretation and report-
ing of received data.
This review hopefully fulfills the main purpose to present
existing approaches to interpretation and presentation of
IHC scoring methods and offers researchers assistance with
the critical selection and application of scores or appro-
priate modifications for the individual scientific question.
Maybe future investigations even develop new “gold stan-
dards” for additional IHC parameters, which would achieve
a better comparability between different study results.
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